Obstacles and opportunities in the clinical development of targeted therapeutics

Progress in Drug Research

Volumn 63, Issue , 2005, Pages 19-41

  Dy, Grace K ^a   Adjei, Alex A ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CYTOSTATIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IMATINIB; IRINOTECAN; MONOCLONAL ANTIBODY; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RITUXIMAB; SORAFENIB; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BREAST CANCER; CLINICAL TRIAL; COLON CANCER; CYTOSTASIS; CYTOTOXICITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOPROLIFERATIVE DISEASE; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DRUG DESIGN; HUMANS; NEOPLASMS; PATIENT SELECTION; RESEARCH DESIGN;

EID: 26044464329     PISSN: 0071786X     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (74)

1. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10: 789-799
2. De Vita V, Hellman S, Rosenberg S (eds) (2001) Cancer principles and practice of oncology, 6th edition. Lippincott Williams and Wilkins, Philadelphia
3. Weinstein IB (2002) Cancer. Addiction to oncogenes: the Achilles heal of cancer. Science 297: 63-64
4. Nowak MA, Iwasa Y, Michor F (2004) Dynamics of cancer progression. Nat Rev Cancer 4: 197-205
5. Skinner J, Bounacer A, Bond JA, Haughton MF, deMicco C, Synford-Thomas D (2004) Opposing effects of mutant ras oncoprotein on human fibroblast and epithelial cell proliferation: implications for models of human tumorigenesis. Oncogene 23: 5994-5999
6. Aggarwal BB (2004) Nuclear factor-κB. The enemy within. Cancer Cell 6: 203-208
7. Byfield SD, Roberts AB (2004) Lateral signaling enhances TGF-beta response complexity. Trends Cell Biol 14: 107-111
8. Overwijk WW, Restifo NP (2000) Autoimmunity and the immunotherapy of cancer: targeting the 'self' to destroy the 'other'. Crit Rev Immunol 20: 433-450
9. Rossman ED, Lundin J, Lenkei R, Mellstedt H, Osterborg A (2001) Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2: 300-306
10. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037
11. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRuss P, Rischin D, Sauleda S, Gee J et al (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20: 110-124
12. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Ishiwaki Y, Vansteenkiste J, Kudoh S, Rschin D et al (2003) A multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (THE IDEAL 1 Trial). J Clin Oncol 21: 2237-2246
13. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290: 2149-2158
14. Eisenhauer EA, O'Dwyer PJ, Christian M, Humphrey JS (2000) Phase I clinical trial design in cancer drug development. J Clin Oncol 18: 684-692
15. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman DC (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19: 843-850
16. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184-2191
17. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434
18. Kabbinavar F, Hurwitz H, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65
19. Fischer PM (2004) The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Curr Med Chem 11: 1563-1583
20. Xiong HQ, Herbst R, Faria SC, Scholz C, Davis D, Jackson EF, Madden T, McConkey D, Hicks M, Hess K et al (2004) A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs 22: 459-466
21. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L et al (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of FTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21: 3955-3964
22. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D (2004) The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45: 17-21
23. Griffin JL, Shockcor JP (2004) Metabolic profiles of cancer cells. Nat Rev Cancer 4: 551-561
24. 1H NMR diffusion spectroscopy of pf BT4C rat glioma during thymidine kinase-mediated gene therapy in vivo: identification of apoptotic response. Cancer Res 58: 3791-3799
25. Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P et al (2003) Magnetic resonance spectroscopic pharmacodynamic markers of HSP90 inhibitor, 17-allylamino-17- demethoxygeldanamycin, in human colon cancer models. J Natl Cancer Inst 95: 1624-1633
26. Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH (2000) Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res 6: 2318-2325
27. Drevs J (2003) Soluble markers for the detection of hypoxia under antiangiogenic treatment. Anticancer Res 23: 1159-1161
28. Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS (2003) Surrogate markers in antiangiogenesis clinical trials. Br J Cancer 89: 8-14
29. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC (2000) Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 19: 265-272
30. Rinehart J, Adjei AA, LoRusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP et al (2004) Multicenter Phase II study of the oral MEK inhibitor, CI-1040 in patients with advanced non-small cell lung, breast, colon and pancreatic cancer. J Clin Oncol 22: 4456-4462
31. Simon R, Wittes RE, Ellenberg SS (1985) Randomized phase II clinical trials. Cancer Treat Rep 69: 1375-1381
32. Liu PY, LeBlanc M, Desai M (1999) False positive rates of randomized phase II designs. Control Clin Trials 20: 343-352
33. Perrone F, Di Maio M, De Maio E, Maione P, Ottaiano A, Pensabene M, De Lorenzo G, Lombardi AV, Signoriello G, Gallo C (2003) Statistical design in phase II clinical trials and its application in breast cancer. Lancet Oncol 4: 305-311
34. Sylvester RJ (1988) A bayesian approach to the design of phase II clinical trials. Biometrics 44: 823-836
35. Amery W, Dony J (1975) A clinical trial design avoiding undue placebo treatment. J Clin Pharmacol 15: 674-679
36. Rosner GL, Stadler W, Ratain MJ (2002) Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 20: 4478-4484
37. Leber PD, Davis CS (1998) Threats to the validity of clinical trials employing enrichment strategies for sample selection. Control Clin Trials 19: 178-187
38. Zee B, Melnychuk D, Dancey J, Eisenhauer E (1999) Multinomial phase II cancer trials in incorporating response and early progression. J Biopharm Stat 99: 351-363
39. Mick R, Crowley JJ, Carroll RJ (2000) Phase II clinical trial design for nocytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials 21: 343-359
40. Liu PY, Dahlberg S, Crowley J (1993) Selection designs for pilot studies based on survival. Biometrics 49: 391-398
41. Schaid DJ, Ingle JN, Wieand S, Ahman DL (1988) A design for phase II testing of anticancer agents within a phase III clinical trial. Control Clin Trials 9: 107-118.
42. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Ketih E, Levin WJ, Stuart SG, Udove J, Ullrich A et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712
43. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726
44. Slamon DJ, Leyland-Lones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann w, Wolter J, Pegram M et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpressed HER2. N Engl J Med 344: 783-792
45. Shan D, Ledbetter JA, Press OW (1998) Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91: 1644-1652
46. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M (1997) FcγRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-48L/R/H phenotype. Blood 90: 1109-1114
47. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99: 754-758
48. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen C-J, Van Den Abbeele AD, Druker BJ et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349
49. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen C-J, Joseph N, Singer S, Griffith DJ, Haley A, Town A et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299: 708-710
50. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139
51. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ et al (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500
52. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, von Pawel J, Pluzanska A et al (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 22: 777-784
53. Herbst RS, Giaccone G, Schiller J, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA et al (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial - INTACT 2. J Clin Oncol 22: 785-794
54. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, Brennscheidt U, De Rosa F, Mueller B, Von Pawel J (2004) Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 22(14S): 7010
55. Herbst RS, Prager D, Hermann R, Miller V, Fehrenbacher L, Hoffman P, Johnson B, Sandler AB, Mass R, Johnson DH (2004) TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 22(14S): 7011
56. Sirotnak FM, Zakowsky MF, Miller VA, Scher HI, Kris MG (2000) Efficacy of cytotoxic agents against human tumor xenographs is markedly enhanced by coadministration of ZD1839 (Iressa) an inhibitor of tyrosine kinase. Clin Cancer Res 6: 4885-4892
57. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6: 2053-2063
58. nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol 22(14S): 7022
59. Di Gennaro E, Barbarino M, Bruzzese F, de Lorenzo S, Caraglia M, Abbruzzese A, Avallone A, Comella P, Caponigro F, Pepe S et al (2003) Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 195: 139-150
60. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP et al (1997) Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 56: 3666-3669
61. Solit DB, She Y, Moasser M, Hudis C, Kris M, Scher H, Rosen N, Sirotnak FM (2003) Pulsatile administration of the EGF receptor inhibitor (Iressa, ZD1839) is significantly more effective that continuously dosing for sensitizing tumors to Taxol. Clin Cancer Res. 19(16S): 70, abstract A83
62. Genentech press release September 20, 2004: http://www.gene.com/gene/ news/pressreleases/display/.do?method=detail&id=7747&categoryid=3 (Accessed May 2005)
63. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345
64. Miller KD, Rugo HS, Cobleigh MA, Marcom PK, Chap LI, Holmes FA, Fehrenbacher L, Overmoyer BA, Reimann JD, Vassel AV et al (2002) Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) versus capecitabine alone in women with metastatic breast cancer previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 76: S37, abstract 36
65. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Sausville EA (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84: 1424-1431
66. Baguley BC, Marshall ES (2004) In vitro modeling of human tumour behaviour in drug discovery programmes. Eur J Cancer 40: 794-801
67. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, van de Rijn M, Waltham M et al (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24: 227-235
68. Roberts RB, Arteaga CL, Threadgill DW (2004) Modeling the cancer patient with genetically engineered mice: Prediction of toxicity from molecule-targeted therapies. Cancer Cell 5: 115-120
69. Frijhoff AFW, Conti CJ, Senderowicz AM (2004) Advances in molecular carcinogenesis: current and future use of mouse models to screen and validate molecularly targeted anticancer drugs. Mol Carcinog 39: 183-194
70. Hansen K, Khanna C (2004) Spontaneous and genetically engineered animal models: use in preclinical cancer drug development. Eur J Cancer 40: 858-880
71. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009
72. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N et al (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22: 2284-2293
73. Pennie WD, Woodyatt NJ, Aldridge TC, Orphanides G (2001) Application of genomics to the definition of the molecular bass for toxicity. Toxicol Lett 120: 353-358
74. Kennedy S (2002) The role of proteomics in toxicology: identification of biomarkers of toxicity by protein expression analysis. Biomarkers 7: 1-22